SUPPLEMENTARY TABLE. Age group and region\* of women aged 18–64 years† and women aged 18–64 years who had any *BRCA* test† and were enrolled in employer-sponsored health insurance, in metropolitan and nonmetropolitan areas — United States, 2009–2014§

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age group, region, and *BRCA* testing status | 2009 | | 2010 | | 2011 | | 2012 | | 2013 | | 2014 | | Total§ | | |
| Metro | Nonmetro | Metro | Nonmetro | Metro | Nonmetro | Metro | Nonmetro | Metro | Nonmetro | Metro | Nonmetro | Metro | Nonmetro | Total |
| **Women aged 18–64 yrs** | | | | | | | | | | | | | | | |
| **Total** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** |
|  | 13,111,286 | 2,366,872 | 14,865,255 | 2,556,191 | 17,207,843 | 2,900,278 | 17,611,933 | 2,943,169 | 14,905,066 | 2,219,805 | 16,213,843 | 2,409,979 | 38,843,602 | 6,705,602 | 45,549,204 |
| **Age group (yrs)** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | % | % | % |
| 18–34 | 33.1†† | 30.1†† | 33.0†† | 29.6†† | 33.9†† | 30.6†† | 34.8†† | 32.0†† | 34.9†† | 32.0†† | 35.2†† | 31.9†† | 39.9†† | 36.2†† | 39.4 |
| 35–44 | 22.4†† | 20.9†† | 22.4†† | 21.1†† | 21.6†† | 20.1†† | 21.4†† | 19.8†† | 21.2†† | 19.7†† | 20.9†† | 19.5†† | 21.1†† | 20.0†† | 21.0 |
| 45–54 | 24.8†† | 26.2†† | 24.9†† | 26.4†† | 24.2†† | 25.4†† | 23.7†† | 24.7†† | 23.4†† | 24.2†† | 23.0†† | 23.9†† | 21.9†† | 23.5†† | 22.1 |
| 55–64 | 19.6†† | 22.8†† | 19.7†† | 22.9†† | 20.3†† | 23.8†† | 20.1†† | 23.5†† | 20.6†† | 24.1†† | 20.9†† | 24.7†† | 17.1†† | 20.3†† | 17.5 |
| **Region¶** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | % | % | % |
| Northeast | 13.7†† | 4.5†† | 16.2†† | 8.5†† | 19.1†† | 13.8†† | 19.3†† | 13.6†† | 20.4†† | 10.9†† | 22.8†† | 15.1†† | 18.6†† | 11.3†† | 17.6 |
| South | 46.0†† | 49.7†† | 38.2†† | 51.3†† | 35.0†† | 47.2†† | 34.7†† | 45.0†† | 32.8†† | 46.0†† | 35.3†† | 46.2†† | 38.4†† | 47.1†† | 39.7 |
| Midwest | 24.5†† | 33.5†† | 23.5†† | 27.6†† | 22.4†† | 27.4†† | 21.9†† | 27.5†† | 19.7†† | 28.2†† | 18.4†† | 27.1†† | 21.5†† | 28.7†† | 22.6 |
| West | 15.6†† | 11.6†† | 21.7†† | 12.5†† | 20.0†† | 11.6†† | 21.4†† | 13.8†† | 24.0†† | 14.9†† | 20.8†† | 11.6†† | 19.8†† | 12.7†† | 18.8 |
| **Women aged 18–64 yrs who had any *BRCA* test** | | | | | | | | | | | | | | | |
| **Total** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** | **No.** |
|  | 13,475 | 1,533 | 16,826 | 1,977 | 21,558 | 2,576 | 25,256 | 2,945 | 33,193 | 3,560 | 38,560 | 4,610 | 147,725 | 17,112 | 164,837 |
| **Age group (yrs)** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | **%** | % | % | % |
| 18–34 | 13.3†† | 11.3†† | 12.5 | 12.9 | 13.9†† | 13.5†† | 15.3†† | 14.4†† | 15.1†† | 16.3†† | 16.4†† | 16.1†† | 14.9†† | 14.7†† | 14.9 |
| 35–44 | 30.1†† | 27.7†† | 29.3 | 28.4 | 28.6†† | 25.0†† | 28.8†† | 26.6†† | 28.3†† | 25.9†† | 28.1†† | 26.1†† | 28.7†† | 26.4†† | 28.4 |
| 45–54 | 36.5†† | 37.3†† | 37.2 | 37.4 | 35.7†† | 36.9†† | 34.6†† | 35.6†† | 33.9†† | 34.5†† | 32.1†† | 32.3†† | 34.4†† | 35.1†† | 34.5 |
| 55–64 | 20.1†† | 23.7†† | 21.0 | 21.2 | 21.7†† | 24.6†† | 21.3†† | 23.5†† | 22.7†† | 23.3†† | 23.4†† | 25.5†† | 22.0†† | 23.9†† | 22.2 |
| **Region¶** | % | % | % | % | % | % | % | % | % | % | % | % | % | % | % |
| Northeast | 19.8†† | 5.8†† | 22.0†† | 11.5†† | 23.3†† | 18.7†† | 22.5†† | 16.0†† | 26.6†† | 13.2†† | 25.3†† | 16.3†† | 23.9†† | 14.4†† | 22.9 |
| South | 45.4†† | 48.1†† | 37.9†† | 48.9†† | 33.4†† | 41.6†† | 34.4†† | 43.4†† | 31.2†† | 48.4†† | 35.4†† | 51.1†† | 35.2†† | 47.4†† | 36.5 |
| Midwest | 21.6†† | 33.7†† | 22.7†† | 26.5†† | 21.7†† | 27.8†† | 21.0†† | 28.9†† | 17.3†† | 26.4†† | 16.7†† | 22.6†† | 19.4†† | 26.7†† | 20.2 |
| West | 13.0†† | 12.3†† | 17.1†† | 13.0†† | 17.9†† | 11.9†† | 19.4†† | 11.7†† | 22.0†††† | 12.0†† | 20.4†† | 10.0†† | 19.2†† | 11.5†† | 18.4 |

**Source:** MarketScan Commercial Claims and Encounters databases.

**Abbreviations:** BRCA = breast cancer (gene); metro = metropolitan; NA = not available; nonmetro = nonmetropolitan.

\* Statistical comparisons of column proportions by chi-square test.

† Women who had *BRCA* testing for Ashkenazi mutations were excluded from the analyses.

**§** Combined data for total sample of women aged 18–64 years are corrected for multiyear enrollment. Data combined across the study period for women aged 18–64 years who had *BRCA* tests, 2009–2014, corrected for the <1% of women who had *BRCA* testing in >1 year.

**¶** Region percentages might not add up to 100% because of missing data.

†† p<0.05.